Insulet Corporation is gaining momentum in the diabetes management sector with the introduction of its Omnipod 5 automated insulin delivery system, bolstering its product offerings. The company's stock is currently priced at $156.25, supported by a robust market capitalization of $10.71 billion and a favorable price-to-earnings ratio of 23.93. Despite facing a short interest of 4.29%, Insulet's global presence, a strategic leadership team, and a growing workforce of 5,400 underscore its commitment to improving the lives of insulin-dependent diabetes patients.
“Insulet Corporation · develops, manufactures, and sells · insulin delivery systems · for people with insulin-dependent diabetes”
“Insulet Corporation · offers · Omnipod platform products · including Omnipod 5 automated insulin delivery system”
“Insulet Corporation · headquartered in · Acton, Massachusetts”
“Insulet · is headquartered in · Acton, Massachusetts”
“Insulet · is a global company · with growing reach”
“Insulet Corp. · is · a medical device company”
“Insulet Corp. · engages in the · development, manufacture, and marketing of an insulin infusion system · for people with insulin-dependent diabetes”
“Insulet Corp. · specializes in · diabetes supplies · including the OmniPod System”
“Insulet Corp. · has · 5,400 employees”
“Insulet Corp. · was founded in · 2000”
“Insulet Corp. · engages in · development, manufacture, and marketing of an insulin infusion system · for people with insulin-dependent diabetes”
“Insulet Corp. · specializes in · diabetes supplies”
